Foundry Partners, LLC - BIO-TECHNE CORP ownership

BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 431 filers reported holding BIO-TECHNE CORP in Q4 2020. The put-call ratio across all filers is 1.11 and the average weighting 0.2%.

About BIO-TECHNE CORP

Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.

Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.

In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.

Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.

Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

Quarter-by-quarter ownership
Foundry Partners, LLC ownership history of BIO-TECHNE CORP
ValueSharesWeighting
Q2 2023$379,253
+10.0%
4,6460.0%0.02%
+4.5%
Q1 2023$344,687
+91328.9%
4,646
+2.0%
0.02%
+4.8%
Q4 2022$377
-99.9%
4,554
+287.2%
0.02%0.0%
Q3 2022$334,000
-6.2%
1,176
+14.5%
0.02%0.0%
Q2 2022$356,000
-20.0%
1,0270.0%0.02%
-8.7%
Q1 2022$445,000
-24.8%
1,027
-10.3%
0.02%
+9.5%
Q4 2021$592,000
+9.6%
1,145
+2.7%
0.02%
+10.5%
Q3 2021$540,000
+7.6%
1,1150.0%0.02%
+11.8%
Q2 2021$502,000
-82.5%
1,115
-85.1%
0.02%
-81.9%
Q1 2021$2,868,000
-23.2%
7,508
-36.1%
0.09%
-35.6%
Q4 2020$3,733,000
+15.3%
11,756
-10.0%
0.15%
-7.0%
Q3 2020$3,238,000
-7.1%
13,069
-1.0%
0.16%
-7.6%
Q2 2020$3,486,000
+22.6%
13,201
-11.9%
0.17%
+6.2%
Q1 2020$2,843,000
-13.6%
14,9920.0%0.16%
+29.0%
Q4 2019$3,291,000
+9.7%
14,992
-2.2%
0.12%0.0%
Q3 2019$3,000,000
-6.3%
15,331
-0.2%
0.12%
-1.6%
Q2 2019$3,203,000
+4.7%
15,364
-0.3%
0.13%
+2.4%
Q1 2019$3,059,000
-46.5%
15,407
-53.0%
0.12%
+4.2%
Q4 2018$5,721,000
+70.8%
32,798
+99.8%
0.12%
-7.1%
Q3 2018$3,350,000
+36.7%
16,412
-0.9%
0.13%
+27.0%
Q2 2018$2,451,000
-7.6%
16,569
-5.7%
0.10%
-11.5%
Q1 2018$2,653,000
+18.2%
17,564
+1.3%
0.11%
+21.5%
Q4 2017$2,245,000
-36.5%
17,332
-40.7%
0.09%
-34.0%
Q3 2017$3,535,00029,2380.14%
Other shareholders
BIO-TECHNE CORP shareholders Q4 2020
NameSharesValueWeighting ↓
Broadcrest Asset Management, LLC 300,000$24,489,00021.05%
Montanaro Asset Management Ltd 388,800$31,737,7445.02%
Sandhill Capital Partners LLC 502,447$41,014,7753.74%
Brown Capital Management 3,160,892$258,023,6143.66%
DF DENT & CO INC 3,275,617$267,388,6403.62%
Ownership Capital B.V. 2,282,104$186,288,1503.26%
Jackson Square Partners, LLC 1,361,789$111,162,8363.24%
STONE RUN CAPITAL, LLC 88,135$7,194,4603.20%
Pembroke Management, LTD 339,591$27,720,8132.99%
Summit Creek Advisors LLC 283,693$23,157,8602.90%
View complete list of BIO-TECHNE CORP shareholders